Biopharmaceutical CMO & CRO Market: Asia Pacific is expected to grow at a significant CAGR

 Biopharmaceutical CMO and CRO Industry Overview

The global biopharmaceutical CMO and CRO market size was valued at USD 29.4 billion in 2021 and is anticipated to grow at a compound annual growth rate (CAGR) of 6.6% over the forecast period.

There was unprecedented growth in 2020 due to the COVID-19 pandemic. The rising investments in the biopharmaceutical industry by the prominent participants to enhance their productivity and efficiency have driven the bio manufacturers to increase their focus on outsourcing activities. Currently, biopharma companies have begun outsourcing the resource and capital-intensive steps and, in a few cases, the entire chain of biomanufacturing, thereby boosting the demand for contract-based services.

 

Gather more insights about the market drivers, restrains and growth of the Global Biopharmaceutical CMO And CRO Market


The coronavirus pandemic has resulted in disruptions in the supply chain of the overall pharmaceutical industry. However, the biopharmaceutical CMO & CRO has responded well to the outbreak as such organizations are the beneficiaries of supply chain disruptions. The CMOs and CROs based in the western hemisphere would especially benefit during the pandemic. For instance, the Australian government partnered with Sandoz and plans to provide an investment of around 50 million euros to spur the production of integrated antibiotics in Europe. Mergers and acquisitions help CMOs offer integrated bioprocessing services to their clients, which, in turn, makes CMOs/CROs an attractive and feasible option for the rapid product launch.

In recent years, the biopharmaceutical industry has witnessed a significant number of consolidations. These consolidations were mainly aimed at business expansion and to stay competitive in the biopharmaceutical contract manufacturing and services market. Although the biopharmaceutical CMO & CRO industry itself is relatively developed, the inception of new bioprocessing tools, novel therapeutics, and the priority shifts in the bio/pharmaceutical industry pertaining to products has increased the pressure on the contract biomanufacturers. As a result, CDMOs are adopting different business models for addressing the needs of their clients and stakeholders in the best possible way.  

Furthermore, the integration of single-use systems in production facilities helps the CMOs to economically expand the manufacturing capacity. The single-use products offer fast turnaround and limit allied activities, such as cleaning and changeover validation. However, the contract negotiations between CMOs and customers are observed to be difficult owing to the regulatory landscape and complexity of service. Clients and CMOs are facing issues pertaining to the IP rights, warranty & liabilities, prices & timelines, which increases the complexity of negotiations.

 

Browse through Grand View Research's Medical Devices Industry Research Reports.

  • Endoscopy Procedures Estimates Market - The global endoscopy procedures estimates market was valued at 222.9 million procedures in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 1.3% from 2022 to 2030.

 

  • Sacroiliac Joint Fusion Market - The global sacroiliac joint fusion market size was valued at USD 539.30 million in 2021 and is estimated to grow at a compound annual growth rate (CAGR) of 19.0% from 2022 to 2030.

 

Biopharmaceutical CMO And CRO Market Segmentation

Grand View Research has segmented the global biopharmaceutical CMO & CRO market on the basis of source, service, product, and region:

  • Biopharmaceutical CMO & CRO Source Outlook (Revenue, USD Million, 2017 - 2030)
    • Mammalian
    • Non-mammalian

 

  • Biopharmaceutical CMO & CRO Service Outlook (Revenue, USD Million, 2017 - 2030)
    • Contract Manufacturing
      • Process Development
        • Downstream
        • Upstream
      • Fill & Finish Operations
      • Analytical & QC Studies
      • Packaging
    • Contract Research
      • Oncology
      • Inflammation & Immunology
      • Cardiology
      • Neuroscience
      • Others

 

  • Biopharmaceutical CMO & CRO Product Outlook (Revenue, USD Million, 2017 - 2030)
    • Biologics
      • Monoclonal antibodies (MAbs)
      • Recombinant Proteins
      • Vaccines
      • Antisense, RNAi, & Molecular Therapy
      • Others
    • Biosimilars

 

  • Biopharmaceutical CMO & CRO Regional Outlook (Revenue, USD Million, 2017 - 2030)
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • MEA

 

Market Share Insights

  • November 2021: Lonza published a press release stating their acquisition of the Exosomics Service Unit. This aims at increasing their capacity to develop and manufacture exosomes in the future.
  • December 2021: Discovery Life Sciences completed and announced the acquisition of In Vitro ADMET Laboratories (IVAL). With this move, the company aims to expand its skilled workforce allowing them to competently cater to the rising outsourcing of research activities.


Key Companies profiled:

Some prominent players in the Biopharmaceutical CMO And CRO market include

  • Boehringer Ingelheim GmbH
  • Lonza Group AG
  • Inno Biologics Sdn Bhd
  • Rentschler Biopharma SE
  • JRS Pharma
  • Biomeva GmbH
  • ProBioGen AG
  • Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  • Toyobo Co., Ltd.
  • Samsung Biologics

 

Order a free sample PDF of the Biopharmaceutical CMO And CRO Market Intelligence Study, published by Grand View Research. 

Comments

Post a Comment

Popular posts from this blog

Drug Addiction - Pipeline Review, H1 2017 Market Overview and trends research report

Radiant insights, inc latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction - Pipeline Review, H1 2017, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape. Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes. Report Highlights Radiant insights, inc Pharmaceutical and Healthcare latest pipeline guide Drug Addiction - Pipeline Review, H1 2017, p...
Read more

All Countries Dialyzer Industry 2013-2028 - Market Size, Share, Outlook, Growth, Key Players and Forecast

The global Dialyzer market was valued at $XX million in 2018, and Radiant Insights, Inc analysts predict the global market size will reach $XX million by the end of 2028, growing at a CAGR of XX% between 2018 and 2028. This report provides detailed historical analysis of global market for Dialyzer from 2013-2018, and provides extensive market forecasts from 2019-2028 by region/country and subsectors. It covers the sales volume, price, revenue, gross margin, historical growth and future perspectives in the Dialyzer market. Download Free Sample Report @ https://www.radiantinsights.com/research/2013-2028-report-on-global-dialyzer-market/request-sample Leading players of Dialyzer including: • Fresenius Medical Care • Baxter • Nipro • Asahi Kasei • Toray • B.Braun • Nikkiso • Medtronic • Kawasumi • Medica • Wego • Lengthen • Peony Medical • Chengdu OCI • Bain Medical Equipment Market split by Type, can be divided into: • Flat Type Dialyzer • Coil Tube Dialyzer • Ho...
Read more

Insights into the Medical Waste Disposal Category: A Comprehensive Procurement Intelligence Report

  Medical Waste Disposal Category Overview The medical waste disposal category is anticipated to grow at a CAGR of 6.0% from 2023 to 2030. Appropriate disposal of medical trash is the key challenge for healthcare providers across the globe. Rising awareness about the benefits of proper medical waste management for treatment, recycling, and disposal of medical trash has boosted the growth of the category. According to the World Health Organization Study Report 2022, countries with low income generate over 0.2 kg of medical trash per day per hospital bed, whereas countries with high income generate hazardous waste of up to 0.5 kg per hospital bed each day. Moreover, rising government initiatives and strict rules and regulations for waste management are also expected to drive the category. For instance, in December 2022, an MOU was signed between the Center for Health Environment Research and Development and Can Tho Central General Hospital under USAID’s Reducing Pollution Project. T...
Read more